A Lesion-adaptive Segmentation Approach for Tumor Delineation on FDG PET/CT in Diffuse Large B-cell Lymphoma Patients.

No abstract is available for this paper.

• Publication year

  2026

• Venue

  European Journal of Nuclear Medicine and Molecular Imaging

• Publication date

  2026-02-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00259-026-07768-8PMID 41689647
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluating ΔMTV%, ΔDmax%, and %ΔSUVmax of 18F-FDG PET/CT for mid-treatment efficacy and prognosis in diffuse large B-cell lymphoma

  2025cited by this paper
• Validation of an Artificial Intelligence–Based Prediction Model Using 5 External PET/CT Datasets of Diffuse Large B-Cell Lymphoma

  2024cited by this paper
• Predictive value of Dmax and %ΔSUVmax of 18F-FDG PET/CT for the prognosis of patients with diffuse large B-cell lymphoma

  2023cited by this paper
• Evaluation of Semiautomatic and Deep Learning–Based Fully Automatic Segmentation Methods on [18F]FDG PET/CT Images from Patients with Lymphoma: Influence on Tumor Characterization

  2023cited by this paper
• Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma

  2023cited by this paper
• Role of Artificial Intelligence in PET/CT Imaging for Management of Lymphoma.

  2023cited by this paper
• Deep Learning Approach to Automatize TMTV Calculations Regardless of Segmentation Methodology for Major FDG-Avid Lymphomas

  2022cited by this paper
• Deep learning–based tumour segmentation and total metabolic tumour volume prediction in the prognosis of diffuse large B-cell lymphoma patients in 3D FDG-PET images

  2022cited by this paper
• 18F-FDG PET-Based Combined Baseline and End-Of-Treatment Radiomics Model Improves the Prognosis Prediction in Diffuse Large B Cell Lymphoma After First-Line Therapy.

  2022cited by this paper
• Molecular Determinants of Clinical Outcomes In a Real-World Diffuse Large B-cell Lymphoma Population.

  2022cited by this paper
• Full automation of total metabolic tumor volume from FDG-PET/CT in DLBCL for baseline risk assessments

  2022cited by this paper
• 18F-FDG PET Maximum-Intensity Projections and Artificial Intelligence: A Win-Win Combination to Easily Measure Prognostic Biomarkers in DLBCL Patients

  2022cited by this paper
• Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index

  2022cited by this paper
• Interobserver Agreement on Automated Metabolic Tumor Volume Measurements of Deauville Score 4 and 5 Lesions at Interim 18F-FDG PET in Diffuse Large B-Cell Lymphoma

  2021cited by this paper
• Correlation of 18-fluorodeoxyglucose PET/computed tomography parameters and clinical features to predict outcome for diffuse large B-cell lymphoma

  2021cited by this paper
• Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements

  2021cited by this paper
• Risk stratification in diffuse large B cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT.

  2020cited by this paper
• Deep-Learning 18F-FDG Uptake Classification Enables Total Metabolic Tumor Volume Estimation in Diffuse Large B-Cell Lymphoma

  2020cited by this paper
• Optimizing Workflows for Fast and Reliable Metabolic Tumor Volume Measurements in Diffuse Large B Cell Lymphoma

  2020cited by this paper
• Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET/CT for total metabolic tumour volume prediction using a convolutional neural network.

  2020cited by this paper
• Comparison of 11 automated PET segmentation methods in lymphoma

  2020cited by this paper
• Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84).

  2020cited by this paper
• Automated Segmentation of Baseline Metabolic Total Tumor Burden in Diffuse Large B-Cell Lymphoma: Which Method Is Most Successful? A Study on Behalf of the PETRA Consortium

  2020cited by this paper
• Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: A meta-analysis

  2019cited by this paper
• PET-derived tumor metrics predict DLBCL response and progression-free survival

  2019cited by this paper
• Molecular Characteristics of Diffuse Large B-Cell Lymphoma and Correlation with Baseline Metabolic Tumor Volume (MTV), Interim Positron Emission Tomography (iPET) and Outcome in the PETAL Trial

  2018cited by this paper
• Prognostic value of baseline, interim and end-of-treatment 18F-FDG PET/CT parameters in extranodal natural killer/T-cell lymphoma: A meta-analysis

  2018cited by this paper
• Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma

  2018cited by this paper
• ATLAAS: an automatic decision tree-based learning algorithm for advanced image segmentation in positron emission tomography

  2016cited by this paper
• Is STAPLE algorithm confident to assess segmentation methods in PET imaging?

  2015cited by this paper
• Metabolic tumor volume on interim PET is a better predictor of outcome in diffuse large B-cell lymphoma than semiquantitative methods

  2015cited by this paper
• Impact of [18F]FDG PET imaging parameters on automatic tumour delineation: need for improved tumour delineation methodology

  2011cited by this paper

• No citing papers are available for this paper.